Relative potency of incobotulinumtoxinA vs onabotulinumtoxinA: A meta-analysis of key evidence

Journal of Drugs in Dermatology

Volumn 11, Issue 6, 2012, Pages 731-736

  Jandhyala, Ravi ^a  

^a Jandhyala Institute   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A;

ARTICLE; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; DRUG POTENCY; HUMAN; META ANALYSIS; NONHUMAN; WRINKLE;

ANIMALS; BOTULINUM TOXINS, TYPE A; CHEMISTRY, PHARMACEUTICAL; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKIN AGING;

EID: 84863558156     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Sattler G, Callander MJ, Grablowitz D, et al. Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. Dermatol Surg. 2010;3:2146-2154.
2. Moers-Carpi M, Tan K, Fulford-Smith A. A multicenter, randomised, double-blind study to evaluate the efficacy of onabotulinumtoxinA (20 units) in the treatment of glabellar lines, when compared to incobotulinumtoxinA (30 units). Poster presented at 7th European Masters in Aesthetic and Anti-Aging Medicine (EMAA), 2011.
3. Hunt T, Clarke K. Potency evaluation of a formulated drug product containing 150-kd botulinum neurotoxin type A. Clin Neuropharm. 2009;32:28-31.
4. Hunt T, Rupp D, Shimizu G, et al. Characterization of SNARE cleavage products generated by formulated botulinum neurotoxin type-a drug products. Toxins (Basel). 2010;2:2198-2212.
5. Lunn DJ, Thomas A, Best N, et al. WinBUGS - a Bayesian modelling framework: concepts, structure, and extensibility. Statistics and Computing. 2000;10:325-337.
6. MRC Biostatistics Unit, Cambridge, UK. The BUGS project. Available at: http://www.mrc-bsu.cam.ac.uk/bugs/. Accessed 18 May 2011.
7. Carruthers JA, Lowe NJ, Menter MA, et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol. 2002;46:840-849.
8. Carruthers A, Carruthers J, Cohen J. A prospective, double-blind, randomized, parallel- group, dose-ranging study of botulinum toxin type a in female subjects with horizontal forehead rhytides. Dermatol Surg. 2003;29:461-467. (Pubitemid 36583142)
9. Harii K, Kawashima M. A double-blind, randomized, placebo-controlled, two-dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects. Aesthetic Plast Surg. 2008;32:724-730.
10. Wu Y, Zhao G, Li H, et al. Botulinum toxin type A for the treatment of glabellar lines in Chinese: a double-blind, randomized, placebo-controlled study. Dermatol Surg. 2010;36:102-108.
11. Ascher B, Zakine B, Kestemont P, et al. A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. J Am Acad Dermatol. 2004;51:223-233.
12. Brandt F, Swanson N, Baumann L, et al. Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety. Dermatol Surg. 2009;35:1893-1901.
13. Rzany B, Ascher B, Fratila A, et al. Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Arch Dermatol. 2006;142:320-326.
14. Rappl T, Kranzelbinder B, Wiedner M, et al. Is there a difference in the persistence, efficacy and tolerability of three botulinum toxin-A containing products: A double-blind, randomised study. Poster presented at Int Soc Phy Rehabil World Congress, 2009.
15. Prager W, Wissmüller E, Kollhorst B, et al. Comparison of two botulinum toxin type A preparations for treating crow's feet: a split-face, double-blind, proof-of-concept study. Dermatol Surg. 2010;36 Suppl 4:2155-2160.
16. Benecke R, Jost WH, Kanovsky P, et al. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology. 2005;64:1949-1951. (Pubitemid 40800714)
17. Dressler D. Routine use of Xeomin in patients previously treated with Botox: long term results. Eur J Neurol. 2009;16 Suppl 2:2-5.
18. Dressler D. Comparing Botox and Xeomin for axillar hyperhidrosis. J Neural Transm. 2010;117:317-319.
19. Wabbels B, Reichel G, Fulford-Smith A et al. Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm. J Neural Transm. 2011;118:233-239.
20. Roggenkamper P, Jost WH, Bihari K, et al. Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm. 2006;113:303-312. (Pubitemid 43201097)
21. Dressler D, Mander G, Fink K. Measuring the potency labelling of onabotulinumtoxinA (Botox® and incobotulinumtoxinA (Xeomin®) in an LD50 assay. J Neural Transm. 2012;119:13-15.
22. Snapinn S. Noninferiority trials. Curr Control Trials Cardiovasc Med. 2000;1:19-21. (Pubitemid 32219869)